NASDAQ:CNST - Constellation Pharmaceuticals Stock Price, Forecast & News

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

Constellation Pharmaceuticals Inc (NASDAQ:CNST) posted its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.82) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.83) by $0.01. View Constellation Pharmaceuticals' Earnings History.

Constellation Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Constellation Pharmaceuticals.

6 brokerages have issued 1 year price targets for Constellation Pharmaceuticals' shares. Their forecasts range from $40.00 to $65.00. On average, they expect Constellation Pharmaceuticals' stock price to reach $49.00 in the next year. This suggests a possible upside of 34.5% from the stock's current price. View Analyst Price Targets for Constellation Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Constellation Pharmaceuticals.

Media stories about CNST stock have been trending very positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Constellation Pharmaceuticals earned a news sentiment score of 3.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Constellation Pharmaceuticals.

Constellation Pharmaceuticals saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 1,810,000 shares, a decline of 5.7% from the November 28th total of 1,920,000 shares. Based on an average daily volume of 648,100 shares, the days-to-cover ratio is presently 2.8 days. Currently, 15.8% of the company's stock are sold short. View Constellation Pharmaceuticals' Current Options Chain.

Some companies that are related to Constellation Pharmaceuticals include Reata Pharmaceuticals (RETA), Ascendis Pharma A/S (ASND), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), BridgeBio Pharma (BBIO), Allakos (ALLK), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC) and Deciphera Pharmaceuticals (DCPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Canopy Growth (CGC), AT&T (T), Arrowhead Pharmaceuticals (ARWR), Xilinx (XLNX), Keysight Technologies (KEYS), Kodiak Sciences (KOD), NIO (NIO), Snap (SNAP) and Advanced Micro Devices (AMD).

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

Constellation Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Selz Capital LLC (0.03%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Constellation Pharmaceuticals stock include Adrian Senderowicz, Alexandria Venture Investments, Anthony B Evnin, Emma Reeve, Group L P Column, James E Audia, James E Flynn, Of The University Of C Regents and Patrick Trojer. View Institutional Ownership Trends for Constellation Pharmaceuticals.

CNST stock was acquired by a variety of institutional investors in the last quarter, including Selz Capital LLC and Nisa Investment Advisors LLC. Company insiders that have bought Constellation Pharmaceuticals stock in the last two years include Alexandria Venture Investments, Anthony B Evnin, Group L P Column and James E Flynn. View Insider Buying and Selling for Constellation Pharmaceuticals.

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CNST stock can currently be purchased for approximately $36.42.

Constellation Pharmaceuticals has a market capitalization of $1.49 billion. The company earns $-59,920,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Constellation Pharmaceuticals employs 82 workers across the globe.View Additional Information About Constellation Pharmaceuticals.

The official website for Constellation Pharmaceuticals is http://www.constellationpharma.com/.

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]